|
original article |
Journal |
Date |
Title |
Authors Max. 6 Authors |
1 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
新型コロナウイルス感染症下におけるクロマチン構造制御","Regulation of chromatin structure under COVID-19 |
Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Yumiko Imai |
2 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
シングルセル情報とゲノム情報の統合解析によるCOVID-19重症化メカニズムの解明","Elucidating the mechanism of COVID-19 severity by integrative analyses of single-cell and host genetics data |
Edahiro Ryuya, Yuya Shirai, Yusuke Takeshima, Shuhei Sakakibara, Yuta Yamaguchi, Teruaki Murakami, Takayoshi Morita, Yasuhiro Kato, Yu-Chen Liu, Daisuke Motooka, James B Wing, Kyuto Sonehara, Yoshihiko Tomofuji, Ho Namkoong, Hiromu Tanaka, Ho Lee, Koichi Fukunaga, Haruhiko Hirata, Yoshito Takeda, Daisuke Okuzaki, Atsushi Kumanogoh, Yukinori Okada |
3 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
An observational study of post COVID-19 syndrome in Japan using a medical database","メディカルデータベースを用いた日本における新型コロナウイルス感染症の後遺症研究 |
Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Katsuhiko Ozaki, Shinichi Higashiue, Yumiko Imai |
4 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
COVID-19重症度予測シミュレーションと医療機械学習基盤(Medical MLOps)の構築","COVID-19 severity prediction orchestrated in medical MLOps |
Yachie Ayako, Yumiko Imai, Taiko Nishino, Sucheendra Kumar Palaniappan |
5 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
新型コロナウイルスの進化","Evolution of SARS-CoV-2: Now And Then |
Kei Sato |
6 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―07 |
New wave of airway 3D models: More than a proof-of-concept for pandemicpreparedness for industry |
Kazuhiro Ito |
7 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2024―Jan―06 |
ACE2-from fly hearts to the heart of a pandemic","ACE2-from fly hearts to the heart of apandemic |
Josef Penninger |
8 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Inactivation of leukocytes for prevention of severe COVID-19 |
Mutoh-Matsushita Akiko |
9 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Depressive symptoms and cognitive dysfunction in Post Covid-19 Condition |
Noda Takamasa, Kaori Okabe, Yasunari Kanda, Motohiro Nishida |
10 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Population analysis approaches for the spread of covid-19 pandemic in 150 countries |
Koshimichi Hiroki |
11 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure |
Katsuki Wakayama, Kiichi Nakahira, Akihiko Tanaka, Yosuke Hukuda, Jing Zhao, Shin Ohta, Hironori Sagara, Masanori Yoshizumi |
12 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Early prediction of severe COVID-19 progression by a novel lung injury-related biomarker protein |
Arakawa Noriaki |
13 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
The prediction of therapeutic targets and microRNA network in the coronavirus pathogenesis pathway |
Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, Hiroshi Yokozaki, Hiroki Sasaki |
14 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Single cell multiomic analysis of PBMCs from SARS-COV-2 infected patients |
Mara Anais Llamas Covarrubias, Yasuha Kinugasa, Yutaka Suzuki, Yumiko Imai |
15 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
ACE2-like carboxypeptidase B38-CAP suppresses severe acute lung injury induced by aspiration pneumonia and abdominal sepsis as well as SARS-CoV-2 infection |
Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Satoru Nirasawa, Jianbo An, Saori Takahashi, Yumiko Imai, Keiji Kuba |
16 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Development of a SARS-CoV-2 infection model using human iPSC-derived intestinal epithelium |
Yamada Shigeru, Takamasa Noda, Kaori Okabe, Shota Yanagida, Motohiro Nishida, Yasunari Kanda |
17 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Antiviral activity of curcumin and its analogs selected by artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells |
Hirotsugu Komatsu, Takeshi Tanaka, Zhengmao Ye, Ken Ikeda, Takao Matsuzaki, Tamotsu Shiroma, Masato Hosoda, Mayo Yasugi, Koji Teshima |
18 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Strategy for Development of Therapeutics for HIV/AIDS, Chronic Hepatitis B, and SARS-CoV-2/COVID-19 |
Hiroaki Mitsuya |
19 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Dec―25 |
Role of histone ubiquitination in SARS-CoV2 and influenza virus infection |
Kinugasa Yasuha, Midori Hoshizaki, Mara Llamas Covarrubias, Yumiko Imai |
20 |
[GO] |
Folia Pharmacologica Japonica |
2022―Oct―31 |
A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs |
Daiki Ousaka, Masahiro Nishibori |
21 |
[GO] |
Folia Pharmacologica Japonica |
2022―Jun―30 |
Treatment of COVID-19 |
Kazuhiro Yatera |
22 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19 |
Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, Jianbo An, Daichi Utsumi, Satoshi Nagata, Haruhiko Kamada, Wataru Kamitani, Yoshihiro Kawaoka, Yasuhiro Yasutomi, Yumiko Imai, Keiji Kuba |
23 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Development of Therapeutics for HIV/AIDS, CHB and COVID-19 |
Hiroaki Mitsuya |
24 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Development of vaccines and therapeutics for COVID-19. |
Kiyama Ryuichi |
25 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs |
Daiki Ousaka, Dengli Wang, Masahiro Nishiboli |
26 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Human iPSC-based models to evaluate COVID-19 drugs |
Yasunari Kanda |
27 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
PMDA's efforts to promote medical innovation in the coronavirus pandemic |
Yasuhiro Fujiwara |
28 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
The coronavirus-related signaling pathway networks and prediction modeling with activity plots. |
Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, Hiroshi Yokozaki, Hiroki Sasaki |
29 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Eco-pharma research focusing on ACE2-mediated SARS-CoV-2 entry |
Kato Yuri, Yasunari Kanda, Motohiro Nishida |
30 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Characteristics of SARS-CoV-2 mRNA/LNP vaccines and their official verification |
Hanada Kentaro |
31 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
SARS-CoV-2 research using stem cell and organ-on-a-chip technologies |
Takayama Kazuo |
32 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice |
Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, Yoshihiro Kawaoka, Keiji Kuba, Yasuhiro Yasutomi |
33 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2022―Mar―20 |
Development of artificial antibody against receptor binding domain of SARS-CoV-2 spike protein. |
Masahiro Oike, Hirotaka Takahashi, Tatsuya Sawasaki |
34 |
[GO] |
Folia Pharmacologica Japonica |
2022―Feb―28 |
Role of ACE2 in COVID-19 |
Yumiko Imai |
35 |
[GO] |
Folia Pharmacologica Japonica |
2022―Feb―28 |
Engineered ACE2 receptor has a potential for a new therapy of COVID-19 |
Yumi Itoh, Hajime Enatsu, Akira Takada, Toru Okamoto |
36 |
[GO] |
Folia Pharmacologica Japonica |
2022―Feb―28 |
Development of COVID-19 drugs using human iPS cell technology |
Shigeru Yamada, Yasunari Kanda |
37 |
[GO] |
Folia Pharmacologica Japonica |
2022―Feb―28 |
Eco-pharma research aimed at developing COVID-19 therapeutic agent |
Yuri Kato, Kazuhiro Nishiyama, Akiyuki Nishimura, Motohiro Nishida |
38 |
[GO] |
Folia Pharmacologica Japonica |
2022―Feb―28 |
Drug screening for COVID-19 using supercomputer “Fugaku” |
Yasushi Okuno |
39 |
[GO] |
Folia Pharmacologica Japonica |
2021―Dec―31 |
COVID-19 drug candidate pipeline, an overview |
Hiroyuki Sugiyama |
40 |
[GO] |
Folia Pharmacologica Japonica |
2021―Dec―31 |
Remdesivir for COVID-19 |
Yasuhisa Fujita |
41 |
[GO] |
Folia Pharmacologica Japonica |
2021―Dec―31 |
Drug repositioning to combat COVID-19 using artificial intelligence system |
Norihisa Shindo, Hiroyoshi Toyoshiba |
42 |
[GO] |
Folia Pharmacologica Japonica |
2021―Dec―31 |
Contribution to development of remedies for COVID-19: focusing on Eritoran |
Kappei Tsukahara |
43 |
[GO] |
Folia Pharmacologica Japonica |
2021―Oct―31 |
Responses to the COVID-19 pandemic and its impacts on pharmacology education in the universities and colleges in Japan: nationwide emergency survey jointly conducted by the Physiological Society of Japan and the Japanese Pharmacological Society |
Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Satoshi Tanaka, Masabumi Minami |
44 |
[GO] |
Folia Pharmacologica Japonica |
2021―Apr―30 |
Therapeutic potential of nanocurcumin in COVID-19 |
Koji Teshima |
45 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Construction of the multi-layer omics data generation / analysis platform that contributes to the precision medicine of COVID-19 |
Yumiko Imai |
46 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Treatment of COVID-19 |
Kazuhiro Yatera |
47 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Remdesivir for COVID-19 |
Yasuhisa Fujita |
48 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
COVID-19 Drug Candidate Pipeline, An Overview |
Hiroyuki Sugiyama |
49 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model |
Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, Masaki Imai, Saori Takahashi, Daichi Utsumi, Jianbo An, Satoshi Nagata, Haruhiko Kamada, Yoshihiro Kawaoka, Yasuhiro Yasutomi, Yumiko Imai, Keiji Kuba |
50 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Nationwide Emergency Survey Results on the Response to COVID-19 Pandemic and Its Effect on Pharmacological Education Conducted in the Department of Pharmacology in Universities and Colleges Jointly by the Physiology Society of Japan and the Japanese Pharmacological Society. |
Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Tomoyuki Tanaka, Masabumi Minami |
51 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Eco-pharma research aimed at developing COVID-19 therapeutic agent |
Kato Yuri, Motohiro Nishida |
52 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Drug repositioning to combat COVID-19 using artificial intelligence system |
Norihisa Shindo, Hiroyoshi Toyoshiba |
53 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Drug Screening for COVID-19 using Supercomputer "Fugaku" |
Yasushi Okuno |
54 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Contribution to Development of Remedies for COVID-19: Focusing on Eritoran |
Kappei Tsukahara |
55 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2021―Mar―20 |
Investigation of genetic variants in SARS-CoV-2-interacting molecules of ACE2, TMPRSS2 and TLR3/7/8 across populations |
Lee Ji-Won, In-Hee Lee, Sek Won Kong, Tadahiro Iimura |
56 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2020―Mar―17 |
Treatment to prevent the development of severe COVID-19 |
Yumiko Imai |
57 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2020―Mar―17 |
In silico approaches to drug repositioning for COVID-19 at AMED-BINDS |
Takatsugu Hirokawa, Sekijima Masakazu, Shigenori Tanaka, Haruki Nakamura |
58 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2020―Mar―17 |
Nonstructural proteins of Novel Coronavirus (SARS-CoV-2) |
Wataru Kamitani |
59 |
[GO] |
Proceedings for Annual Meeting of The Japanese Pharmacological Society |
2020―Mar―17 |
The initial response of the laboratory diagnosis team to SARS-CoV-2 in Japan and the current situation |
Makoto Takeda |